Abstract 484P
Background
In South Korea, tx for patients (pts) with stage I–IIIA NSCLC is resection, ± systemic tx for stage II and select stage III disease. Osimertinib is a 3rd-generation EGFR-TKI approved as adjuvant tx for resected stage IB–IIIA EGFRm NSCLC, based on ADAURA trial results. To understand rw data prior to adjuvant osimertinib approval, we report EGFR mutation types, tx patterns / outcomes from the South Korean cohort of a global retrospective rw study.
Methods
Medical records of eligible pts (≥18 years [yrs] with resected stage IA–IIIA NSCLC and a positive EGFRm test result, diagnosed between 01 Jan 2014–31 Dec 2017), were assessed from diagnosis (Dx) until last follow-up/death or 31 Dec 2020. Primary objectives included: EGFR mutation type and frequency, tx patterns and overall survival (OS). Site of first recurrence was a secondary objective.
Results
Of 200 pts in South Korea with EGFRm NSCLC, 95 (48%) had Ex19del and 87 (44%) L858R. At Dx, median age was 62 yrs (range: 36–83), 133 pts (67%) were female, 145 (73%) were never smokers; 68 pts (34%) had stage IA disease, 43 (22%) IB, 20 (10%) IIA, 15 (8%) IIB, and 54 (27%) IIIA. In total, 90 pts (45%) received surgery only; 74 (37%) had surgery + adjuvant tx only; 22 (11%) had neoadjuvant + surgery + adjuvant tx; 14 (7%) had salvage/post-recurrence tx (see Table). After median follow-up of 54.7 months from Dx (IQR 44.5–70.1), 5-yr OS was 69% (96% in stage IA, 84% IB, 72% IIA, 73% IIB, 26% IIIA). Of 106 pts who received systemic tx with first recurrence data available, 53 had metastatic recurrence, most commonly in the lung (19/53; 36%) and brain (18/53; 34%).
Conclusions
In this rw study of pts in South Korea with resected EGFRm early-stage NSCLC (Dx 2014–2017), 45% of pts received surgery only and <50% received surgery + adjuvant/neoadjuvant tx; 5-yr OS was suboptimal at 69%. Early Dx and EGFR mutation testing are needed to ensure eligible pts have access to suitable adjuvant tx to improve clinical outcomes. Table: 484P
Treatment received, n (%) | Patients in South Korea (N=200) |
Proportion of patients with surgery only | 90 (45) |
Proportion of patients with neoadjuvant and surgery and adjuvant (within 26 weeks of surgery) treatment* | 22 (11) |
Proportion of patients with surgery and adjuvant (within 26 weeks of surgery) treatment only | 74 (37) |
- Chemotherapy | 73 (99) |
- Targeted therapy | 1 (1) |
- Immunotherapy | 0 |
Proportion of patients with surgery and treatment >26 weeks after surgery (post-recurrence/salvage) | 14 (7) |
- Chemotherapy | 1 (7) |
- Targeted therapy | 14 (100) |
- Immunotherapy | 0 |
Percentages may equal to >100% as patients could have received >1 type of systemic treatment. *No patients received neoadjuvant treatment only.
Clinical trial identification
Editorial acknowledgement
The authors would like to acknowledge Rachel Gater, PhD, of Ashfield MedComms, an Inizio Company, for medical writing support that was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (https://www.ismpp.org/gpp-2022).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
M. Ahn: Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Advisory Board, Honoraria: Bristol Myers Squibb, Merck Sharp & Dohme, Ono Pharmaceutical Co., Ltd., Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Alpha Pharmaceutical, AstraZeneca, Bristol Myers Squibb, Merck Sharpe & Dohme, Ono Pharmaceutical Co. Ltd., Roche, Takeda. J.H. Kang: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Boehringer Ingelheim, AstraZeneca, Novartis, Yuhan Corporation, Ono PHARMA, Genexine; Non-Financial Interests, Personal, Research Funding: Daiichi Sankyo, Boehringer Ingelheim; Non-Financial Interests, Personal, Speaker’s Bureau: MSD, AstraZeneca, Roche, Takeda, Novartis, Daiichi Sankyo, Boehringer Ingelheim, Bristol Myers Squibb, Yuhan Corporation, Bayer. S. Kim: Financial Interests, Personal, Advisory Role, Advisory meeting participation: AstraZeneca; Financial Interests, Personal, Advisory Board, Advisory meeting participation: Amgen, Boehringer Ingelheim, Janssen, Novartis, Takeda, Therapex, Yuhan; Financial Interests, Personal, Other, Lecture: Boehringer Ingelheim; Financial Interests, Personal, Research Funding: Yuhan. D. Kahangire: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. S.P. Nagar, K.L. Davis, M. Jimenez: Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor, RTI Solutions received consulting fees: AstraZeneca. M. Jung: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. M. Sandelin: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. B.C. Cho: Financial Interests, Personal, Advisory Board: KANAPH Therapeutic Inc, Bridgebio therapeutics, Cyrus therapeutics, Guardant Health, Oscotec Inc; Financial Interests, Personal, Advisory Role, Consulting fees: Abion, BeiGene, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus therapeutics, Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli Lilly, GI-Cell, Guardant, HK Inno-N, Imnewrun Biosciences Inc., Janssen, Takeda, MSD, Janssen, Medp; Financial Interests, Personal, Member of Board of Directors: Interpark Bio Convergence Corp., J INTS BIO; Financial Interests, Personal, Other, Founder: DAAN Biotherapeutics; Financial Interests, Personal, Research Grant: MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, GIInnovation, GI-Cell, Abion, AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Champions Onoclogy, CJ bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Jans; Financial Interests, Personal, Royalties: Champions Oncology, Crown Bioscience, Imagen; Financial Interests, Personal, Stocks/Shares: TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp., J INTS BIO. All other authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract